Hympavzi is approved for routine prophylaxis to prevent bleeding episodes in US patients six years and above.

With COVID’s windfall over and blockbuster patents expiring, Pfizer is looking for a comeback with its newly built obesity ...

The pharmaceutical outfit has taken a savvy step forward. Now it just needs to repeat the process a few more times.

With promising mid-stage trial results, berobenatide aims to make obesity treatment more convenient without compromising ...

The biotech company doesn’t have any obesity drugs on the market. Here’s how it plans to change that, and become an industry ...

Nausea and vomiting rates for the monthly injectable berobenatide came in close to benchmarks set by Novo Nordisk's weekly ...

Pfizer could attract investors if Warsh's "regime change" at the Fed leads to market turbulence.

By Michael Erman NEW YORK, June 6 (Reuters) - Pfizer presented data on Saturday that showed a monthly dose of an experimental ...

June 8 (Reuters) - The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of ...

Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it’s in talks ...

Pfizer is paying Innovent $650 million upfront to partner on cancer drug development, following Bristol Myers Squibb by ...

Lilly disclosed new data that provide more details on the safety and tolerability of its next-generation obesity drug ...